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Introduction
Pulmonary fibrosis is a debilitating disease characterized by the development of  excess fibrous tissue, 
leading to thickening of  the alveolar walls and diminished lung function (1). Idiopathic pulmonary fibro-
sis (IPF), the most common subtype of  interstitial lung disease, affects more than 120,000 Americans and 
claims approximately 40,000 lives each year (2, 3). No cure exists, current treatment options are limited, 
and the average life expectancy upon diagnosis is 3 to 5 years (2–4). In normal settings, injury of  the 
epithelium is counterbalanced by repair mechanisms that restore normal epithelial structure and function 
(5). In cases of  fibrosis, however, this balance is overwhelmed and excessive epithelial damage occurs (5). 
Chronic injury of  the distal airways and subsequent loss of  the bronchiolar and alveolar epithelial cells, a 
common histopathological feature of  IPF, occurs concurrently with the activation and overproliferation 
of  myofibroblasts (5, 6). Lung epithelial cell apoptosis also promotes increased release of  TGF-β, a cru-
cial mediator of  fibrotic remodeling (7), and loss of  these cells is sufficient to drive fibrosis (8). Previous 
studies from our laboratory and others have demonstrated that FAS, a proapoptotic member of  the TNF 
receptor superfamily, is a crucial mediator in the pathogenesis of  fibrosis (6, 8). Activation of  FAS, by 
binding of  FAS ligand (FASL), promotes apoptosis of  bronchiolar and alveolar epithelial cells through 
caspase-3 and -8 (8). Myofibroblasts from IPF patients express FASL and induce FAS-dependent apopto-
sis in lung epithelial cells, promoting an imbalance between these cell types (9).
Idiopathic pulmonary fibrosis (IPF) is a debilitating lung disease characterized by excessive 
collagen production and fibrogenesis. Apoptosis in lung epithelial cells is critical in IPF 
pathogenesis, as heightened loss of these cells promotes fibroblast activation and remodeling. 
Changes in glutathione redox status have been reported in IPF patients. S-glutathionylation, the 
conjugation of glutathione to reactive cysteines, is catalyzed in part by glutathione-S-transferase 
π (GSTP). To date, no published information exists linking GSTP and IPF to our knowledge. We 
hypothesized that GSTP mediates lung fibrogenesis in part through FAS S-glutathionylation, a 
critical event in epithelial cell apoptosis. Our results demonstrate that GSTP immunoreactivity 
is increased in the lungs of IPF patients, notably within type II epithelial cells. The FAS-GSTP 
interaction was also increased in IPF lungs. Bleomycin- and AdTGFβ-induced increases in collagen 
content, α-SMA, FAS S-glutathionylation, and total protein S-glutathionylation were strongly 
attenuated in Gstp–/– mice. Oropharyngeal administration of the GSTP inhibitor, TLK117, at a time 
when fibrosis was already apparent, attenuated bleomycin- and AdTGFβ-induced remodeling, 
α-SMA, caspase activation, FAS S-glutathionylation, and total protein S-glutathionylation. GSTP 
is an important driver of protein S-glutathionylation and lung fibrosis, and GSTP inhibition via the 
airways may be a novel therapeutic strategy for the treatment of IPF.
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FAS-mediated apoptosis is dependent on a variety of  factors, including changes in redox status (10). 
Glutathione (GSH), a thiol-containing tripeptide, is a highly abundant endogenous antioxidant and func-
tions, in part, as a free radical scavenger (10). Decreases in GSH and increases in GSH disulfide, the oxi-
dized form of  GSH, have been reported in IPF patients (10, 11). GSH can also regulate protein structure 
and function through a process known as S-glutathionylation, the reversible conjugation of  a GSH mole-
cule to reactive cysteine residues in proteins (10). Our group has recently demonstrated that FASL binding 
promotes the S-glutathionylation of  cysteine 294 of  FAS in mouse airway epithelial cells and that this 
modification promotes cell surface expression of  FAS and activation of  the caspase cascade (8, 12). The 
exact mechanisms that lead to protein S-glutathionylation (PSSG) in pathobiological settings are not fully 
understood, but it is believed that oxidants such as hydrogen peroxide can oxidize sulfhydryl groups of  pro-
tein cysteine residues to form sulfenic acid intermediates, which are subsequently S-glutathionylated (10).
S-glutathionylation can occur nonenzymatically by directly binding free GSH under conditions of  high 
oxidative stress, but these reactions are believed to be fairly nonspecific and are associated with toxicity and 
cell death (13). Enzymatic PSSG, however, is highly specific and tightly controlled by a variety of  enzymes, 
including glutathione-S-transferases (GSTs), a class of  enzymes critical in phase II drug metabolism (14, 
15). GST π (GSTP), which is expressed primarily in the lung, brain, and gastrointestinal tract (15), is a 
mediator of  S-glutathionylation in lung airway epithelial cells (5, 8, 10) and has been linked to both asthma 
and lung cancer (16, 17).
Despite the aforementioned links between GSTP and FAS S-glutathionylation (FAS-SSG), no pub-
lished reports exist to date on the role of  GSTP-linked PSSG during lung fibrogenesis. Likewise, the effects 
of  either GSTP inhibition or ablation on fibrotic remodeling have not yet been determined. Herein, we 
determined that both global knockout and pharmacological inhibition of  GSTP, using a clinically relevant 
inhibitor, attenuate fibrotic remodeling in two mouse models of  pulmonary fibrosis, in part, through a 
mechanism involving FAS-SSG. Our findings presented herein suggest that GSTP inhibition may be a nov-
el target for the treatment of  IPF and other lung fibroproliferative diseases.
Results
GSTP immunoreactivity and FAS-GSTP interaction are increased in the lungs of  IPF patients. We first determined 
whether GSTP expression was affected in the lungs of  IPF patients. While control tissues exhibited sparse 
weak GSTP immunoreactivity in pneumocytes (Figure 1A; 4 top left images) and weak intensity staining 
in bronchial airway epithelium (Figure 1A; top rightmost image), strong staining was identified in IPF lung 
tissue within reactive type 2 pneumocytes in areas of  active fibrosis (Figure 1A; middle and bottom). These 
areas, which were at the interface of  densely fibrotic and less affected lung tissue, featured loose fibrous tissue 
and fibroblast foci. Marked increases in GSTP immunoreactivity were readily detectable in IPF lung tissues 
in regions of  bronchiolar metaplasia in honeycomb cysts (Figure 1B). GSTP-reactive cells in the latter area 
also expressed pro-surfactant protein C (pro-SPC), a marker of  type II alveolar epithelial cells (Figure 1B). 
Based on our prior studies demonstrating that GSTP interacts with FAS in the lungs of  bleomycin-treated 
mice (8), we next assessed whether a similar interaction between GSTP and FAS was present in the lungs 
of  IPF patients. Results in Figure 1C demonstrate an interaction between GSTP and FAS in 5 of  10 IPF 
patients, while little to no interaction was observed in the control lung tissues. Similarly, using two indepen-
dent mouse models of  lung fibrosis, bleomycin or a TGF-β1-expressing recombinant adenovirus (AdTGFβ), 
we demonstrated increases in GSTP immunoreactivity in lung tissues 2 weeks after administration of  either 
agent, with increases being apparent in bronchiolar epithelium and distal lung regions. Increased GSTP 
immunoreactivity was concurrent with the onset of  fibrotic remodeling (ref. 18 and Figure 1D).
Gstp deficiency attenuates bleomycin- and AdTGFβ-induced collagen content and fibrotic remodeling. To deter-
mine the importance of  GSTP in the pathogenesis of  lung fibrosis, we next subjected Gstp–/– mice (Supple-
mental Figure 1; supplemental material available online with this article; doi:10.1172/jci.insight.85717DS1) 
and their wild-type counterparts to either the bleomycin or AdTGFβ models of  fibrosis. As expected in 
wild-type mice, hydroxyproline and soluble collagen content were significantly increased at 15 and 28 days 
following bleomycin administration. In contrast, bleomycin-induced soluble collagen content was signifi-
cantly attenuated in the Gstp–/– mice (Figure 2, A and B, and Supplemental Figure 2). Although downward 
trends in hydroxyproline content were observed in bleomycin-treated Gstp–/– mice relative to controls, these 
trends did not achieve statistical significance (Figure 2A). Assessment of  collagen deposition by Masson’s 
trichrome staining (Figure 2C) confirmed that bleomycin-induced increases in fibrotic remodeling were 
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Figure 1. GSTP immunoreactivity and FAS-GSTP interaction are increased in the lungs of IPF patients. (A) Evaluation of GSTP immunoreactivity in human 
lung sections from either control or IPF patients (red, GSTP; blue, hematoxylin). Representative images of lung sections from 5 of 14 patients from each group 
are shown. Arrows indicate reactive type 2 pneumocytes. Scale bar: 50 μm. (B) Assessment of pro-SPC immunoreactivity in lung sections from IPF patients. 
Parallel sections from IPF patients were probed for either GSTP or pro-SPC by immunohistochemistry (red, GSTP or pro-SPC as indicated; blue, hematoxylin). 
Scale bar: 50 μm. (C) Assessment of interaction between GSTP and FAS in the lungs of IPF patients. FAS was isolated by immunoprecipitation from whole-lung 
homogenates of both normal and IPF patients, and GSTP was detected by Western blot. Lanes represent individual patients. (D) Evaluation of GSTP immunore-
activity in mouse lungs treated with bleomycin for 15 days or AdTGFβ for 21 days. GSTP was detected by immunohistochemistry (red, GSTP; blue, hematoxylin). 
Scale bar: 50 μm. IPF, idiopathic pulmonary fibrosis; FF, fibroblast foci; GSTP, glutathione-S-transferase π; SPC, surfactant protein C; ad-Ctrl, control adenoviral 
vector; ad-TGF-β, adenoviral vector expressing active TGF-β1.
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attenuated in Gstp–/– mouse lungs. Furthermore, immunoreactivity of  α smooth muscle actin (α-SMA), 
a marker of  activated fibroblasts (19), was also noticeably attenuated in the absence of  Gstp (Figure 2D). 
mRNA expression of  the mesenchymal and fibrosis markers, collagen type 1A1 and 5A1 (Col1a1 and 
Col5a1), fibroblast-specific protein 1 (Fsp1), and fibronectin (Fn1), were also increased following bleomy-
cin administration in wild-type mice (Supplemental Figure 3A). These increases were either significantly 
decreased (Col1a1 and Fsp1) or trended toward being decreased (Col5a1 and Fn1) in Gstp–/– lungs.
Figure 2. GSTP deficiency attenuates bleomycin- and AdTGFβ-induced collagen content and fibrotic remodeling. Wild-type and Gstp–/– mice were 
treated with (A–D) bleomycin for 15 days or (E–H) AdTGFβ for 21 days. (A and B) Assessment of hydroxyproline and soluble collagen content in the lungs 
of wild-type or Gstp–/– mice 15 days after bleomycin administration. (C) Assessment of fibrotic remodeling by Masson’s trichrome staining 15 days after 
bleomycin administration. (D) Detection of α-SMA expression by immunohistochemistry (red, α-SMA; blue, hematoxylin). (E and F) Assessment of 
hydroxyproline and soluble collagen content in the lungs of wild-type or Gstp–/– mice 21 days after AdTGFβ treatment. (G) Assessment of fibrotic remod-
eling by Masson’s trichrome staining 21 days after infection. (H) Assessment of α-SMA immunoreactivity by immunohistochemistry (red, α-SMA; blue, 
hematoxylin). *P < 0.05 relative to PBS or AdCtrl group, †P < 0.05 relative to respective wild-type group by 2-way ANOVA with a Tukey post-test. Scale 
bar: 100 μm. Shown are pooled data from 2 independent experiments (n = 6–11 per group). GSTP, glutathione-S-transferase π; α-SMA, α smooth muscle 
actin; AdCtrl, control adenoviral vector; AdTGFβ, adenoviral vector expressing active TGF-β1.
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We next corroborated these observations in a different fibrosis model by evaluating the impact of  Gstp 
deficiency in mice exposed to AdTGFβ. Similar to the bleomycin model, results in Figure 2, E–H, demon-
strate that AdTGFβ-mediated increases in hydroxyproline, soluble collagen, Masson’s trichrome staining, 
and α-SMA immunoreactivity were strongly attenuated in Gstp–/– mouse lungs. Last, AdTGFβ-induced 
Col1a1 mRNA expression was significantly decreased in Gstp–/– lung tissues (Supplemental Figure 3B).
Gstp deficiency attenuates bleomycin- and AdTGFβ-induced PSSG. To determine how GSTP may be regulat-
ing bleomycin- and AdTGFβ-induced fibrotic remodeling in mouse lungs, we next examined its effects on 
PSSG in these models. While GSTP has been shown to mediate GSH-conjugation reactions, as it pertains 
to the metabolism of  xenobiotics, its ability to catalyze PSSG in vivo remains unclear (20). In mice exposed 
to either bleomycin or AdTGFβ, total PSSG was increased in lung tissues (Figure 3, A and B), consistent 
with previous observations (21). Remarkably, bleomycin- and AdTGFβ-mediated increases in total PSSG 
were almost completely absent in Gstp–/– mice, demonstrating that GSTP is a strong contributor to PSSG 
in these models. Our group has previously shown that FAS-SSG is essential in augmenting epithelial cell 
apoptosis and that FAS is required for the development of  fibrosis (8, 12). Results in Figure 3, C and D, 
demonstrate that FAS-SSG was increased in mouse lungs 15 or 21 days after exposure to either bleomycin 
or AdTGFβ, respectively. In contrast, no increases in FAS-SSG were detected in lung tissues from Gstp–/– 
mice exposed to bleomycin or AdTGFβ. These findings suggest that FAS may be an important target for 
GSTP-catalyzed PSSG and fibrogenesis.
TLK117-mediated GSTP inhibition attenuates bleomycin- and AdTGFβ-induced collagen content. Having 
determined that absence of  Gstp attenuates bleomycin- and AdTGFβ-induced fibrotic remodeling and FAS-
SSG, we next assessed the impact of  pharmacological inhibition of  GSTP on lung fibrotic remodeling. 
The active GSTP inhibitor, TLK117, is a GSH analog and is the active metabolite of  TLK199, which has 
completed phase II clinical trials for myelodysplastic syndrome (22, 23). TLK117 is the most specific GSTP 
inhibitor to date, with a binding affinity greater than GSH itself  and a selectivity for GSTP over 50-fold 
greater than the GSTM and GSTA classes (inhibition constant [Ki] = 0.4 μM) (15, 24–27). No published 
observations on the effects of  TLK117 in settings of  lung fibrotic remodeling yet exist.
We first explored whether TLK117-mediated inhibition of  GSTP can attenuate FASL-induced apop-
tosis. Exposure to FASL significantly increased caspase-3 activity in wild-type mouse lung fibroblasts and 
in Fas-deficient (lpr) fibroblasts in which wild-type Fas has been reconstituted (Figure 4A and Supplemental 
Figure 4). TLK117 pretreatment significantly attenuated FASL-induced caspase-3 activity in these groups. 
In lpr fibroblasts expressing C294A mutant Fas, which is refractory to S-glutathionylation (12), FASL-in-
duced caspase-3 activity was completely attenuated. Further, no effect of  TLK117 was observed in these 
settings, indicating that the ability of  TLK117 to attenuate FASL-induced apoptosis requires functional 
FAS that can be S-glutathionylated. Although TLK117 attenuated FASL-induced caspase-3 activity in type 
II alveolar epithelial cells, activation of  caspase-3 induced by TNF-α and cycloheximide was not affected 
by TLK117 (Figure 4B). Collectively, these findings suggest that the protective effects of  TLK117-mediated 
GSTP inhibition are specific to FAS-mediated apoptosis.
To determine the effects of  TLK117 in lung fibrosis, we first confirmed that oropharyngeal adminis-
tration of  TLK117 inhibits GSTP activity in lung tissues. Four hours after administration of  50 mg/kg 
TLK117, GSTP activity was strongly decreased and remained decreased by about 60% for at least 24 hours 
(Figure 4C). A dose of  25 mg/kg of  TLK117, however, did not significantly affect GSTP activity. We there-
fore used a 50 mg/kg dosing regimen in subsequent studies. To determine the effect of  TLK117-mediated 
GSTP inhibition on preexisting fibrotic remodeling in the bleomycin model, TLK117 was administered 
at 50 mg/kg once every 3 days, starting 14 days after bleomycin administration up to day 26, and mice 
were euthanized on day 28. Mice that had received either bleomycin or PBS concurrently were euthanized 
on day 15 to confirm existence of  remodeling at the onset of  TLK117 treatment (Figure 4D). As demon-
strated in Figure 4, E and F, bleomycin-induced increases in hydroxyproline and soluble collagen content 
were significantly increased at day 15, and both parameters were further increased by day 28. Important-
ly, TLK117-mediated GSTP inhibition significantly attenuated the increase in fibrosis between 15 and 28 
days. No statistically significant differences in hydroxyproline and soluble collagen content were detected 
between the bleomycin-exposed mice that received TLK117 and PBS controls. Masson’s trichrome staining 
confirmed that bleomycin-induced lung fibrotic remodeling was markedly decreased upon TLK117-medi-
ated inhibition of  GSTP (Figure 4G). Similarly, bleomycin-induced α-SMA immunoreactivity was strongly 
attenuated upon TLK117 treatment (Figure 4H).
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To corroborate these findings, a similar TLK117 regimen was used in the AdTGFβ model (Figure 
5A). As expected, hydroxyproline and soluble collagen content were significantly increased 14 days after 
AdTGFβ infection with further increases occurring by day 28. Administration of  TLK117 between days 14 
and 28 significantly attenuated AdTGFβ-mediated increases in hydroxyproline, soluble collagen content, 
Masson’s trichrome reactivity, and α-SMA immunoreactivity (Figure 5, B–E).
TLK117-mediated GSTP inhibition attenuates caspase activation, PSSG, and FAS-GSTP interaction. To 
determine whether TLK117-mediated GSTP inhibition affects bleomycin- and AdTGFβ-induced apop-
tosis in mouse lungs, we measured caspase-3 and -8 activity in whole-lung homogenates from these mice. 
Activation of  the caspase cascade is a crucial event in apoptosis, and we have previously linked it to 
FAS-SSG in type II alveolar epithelial cells (8). Caspase-3 and -8 activities were increased both 15 and 28 
days after bleomycin treatment and were significantly decreased upon TLK117-induced GSTP inhibition 
(Figure 6, A and B). Bleomycin-induced total PSSG was also significantly decreased in mouse lungs 
upon GSTP inhibition (Figure 6C). Further, bleomycin-induced increases in FAS-SSG were significantly 
attenuated upon TLK117 treatment (Figure 6D).
Similar to the bleomycin model, AdTGFβ-mediated increases in caspase-3 and -8 activity, total PSSG, 
and FAS-SSG were strongly attenuated upon GSTP inhibition (Figure 7, A–D). Last, we determined 
whether TLK117 affects the interaction of  GSTP and FAS. Results in Figure 7E demonstrate that FAS-
GSTP association, noticeably increased 14 days after AdTGFβ infection, was significantly decreased by 
TLK117-mediated GSTP inhibition.
Figure 3. GSTP deficiency attenuates bleomycin- and AdTGFβ-induced protein S-glutathionylation. Wild-type and Gstp–/– mice 
were treated with either bleomycin for 15 days or AdTGFβ for 21 days as indicated. (A and B) Detection of total PSSG content in 
mouse lung homogenates with a modified DTNB assay. Shown are pooled data from 2 independent experiments. *P < 0.05 rela-
tive to PBS or AdCtrl group, †P < 0.05 relative to respective wild-type group by 2-way ANOVA with a Tukey post-test (n = 4–11 per 
group). (C and D) Assessment of FAS-SSG content by immunoprecipitation of total PSSG and Western blot for FAS. Statistically 
significant differences between wild-type and Gstp–/– groups treated with either (C) bleomycin or (D) AdTGFβ were determined by 
densitometric analysis. *P < 0.05 by unpaired Student’s t test (n = 3 per group). The data shown in C and D are representative of 1 
of 2 independent experiments. GSTP, glutathione-S-transferase π; FAS-SSG, S-glutathionylated FAS; AdCtrl, control adenovirus; 
AdTGFβ, recombinant adenovirus expressing active TGF-β1; GSH, glutathione; DTT, dithiothreitol; WB, Western blot.
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Discussion
The causes underlying lung fibrogenesis remain largely unknown and are likely multifaceted, but exposure 
to certain irritants, including cigarette smoke, mineral dusts, and radiation, have been shown to induce 
redox perturbations and oxidative stress as well as pulmonary fibrosis (10, 28). Disruption of  redox homeo-
stasis, particularly in the epithelium, can promote acute lung injury and increased apoptosis (10, 29), and 
PSSG has recently emerged as a key mediator of  apoptosis and disease pathogenesis (5, 10). The present 
study demonstrates that both genetic ablation of  Gstp and pharmacological inhibition of  GSTP with the 
clinically relevant inhibitor, TLK117, attenuate increases in collagen content, α-SMA immunoreactivity, 
FAS-SSG, and total PSSG in two different mouse models of  lung fibrosis. GSTP immunoreactivity and an 
interaction between FAS and GSTP were also increased in the lungs of  IPF patients, suggesting potential 
clinical relevance for our observations. For the first time to our knowledge, we have shown that expression 
and activity of  GSTP can promote lung fibrogenesis and that pharmacological inhibition of  this enzyme 
via the airways may represent a novel therapeutic strategy for the treatment of  fibrotic lung disease. Fur-
ther, these results underscore the importance of  GSTP in PSSG, particularly FAS-SSG, and that GSTP 
may mediate lung fibrogenesis in part through this mechanism.
It is not entirely clear, based on our findings, in which cell types GSTP exerts its profibrotic role, giv-
en the widespread increases in GSTP immunoreactivity in lungs from mice with bleomycin- and AdTG-
Fβ-induced lung fibrosis (Figure 1D). Given that GSTP immunoreactivity is increased in lung tissue from 
patients with IPF in reactive type II epithelial cells within areas of  active fibrosis and in pro-SPC-expressing 
cells within areas of  bronchiolization (Figure 1B), it is plausible that GSTP-linked S-glutathionylation in 
type II alveolar epithelial cells contributes to disease pathogenesis. In this regard, chronic injury to type II 
cells and the loss of  their normal restitution are considered important in the pathogenesis of  IPF (30, 31). 
In healthy lungs, GSTP is present in bronchial epithelial cells in which it has been implicated in the detox-
ification of  inhaled pollutants (Figure 1D and ref. 32). Increases in GSTP immunoreactivity observed in 
reactive type II cells and areas of  bronchiolization (Figure 1) may facilitate PSSG reactions that are import-
ant in cell death, including FAS-SSG (5, 10). Observations herein demonstrating that pharmacological 
inhibition or genetic ablation of  GSTP resulted in less caspase-3 and -8 activity and dampened FAS-SSG 
are consistent with a role of  GSTP-linked S-glutathionylation in promoting alveolar type II epithelial cell 
death. It is, however, plausible that, besides FAS, other protein targets for GSTP-catalyzed S-glutathionyla-
tion relevant to lung fibrogenesis exist, and additional studies will be required to elucidate these targets.
The exact mechanisms whereby GSTP facilitates S-glutathionylation reactions are not fully known 
(33–35). GSTP functions as a ligandin, and its binding to target proteins affects their function. The iden-
tity of  GSTP’s target proteins in settings of  fibrosis remains unclear, although we demonstrate herein 
an increased association between GSTP and FAS in mice with AdTGFβ-induced fibrosis and in lung 
tissues from patients with IPF. It remains unclear whether the ability of  GSTP to bind proteins controls 
subsequent S-glutathionylation reactions (36, 37). A recent study demonstrated that complex formation 
of  GSTP1 with AMPK led to enzymatic activation of  GSTP and, in turn, facilitated S-glutathionylation 
(38). We demonstrated herein that administration of  TLK117 into airways attenuated FAS-SSG in asso-
ciation with a decreased interaction between GSTP and FAS (Figure 7, D and E). These data suggest that 
GSTP’s ability to bind FAS is important in the catalysis of  FAS-SSG. Cysteine 294 of  mouse FAS was 
previously demonstrated to be the target of  PSSG, and previous studies from our laboratory demonstrat-
Figure 4. TLK117-induced GSTP inhibition attenuates bleomycin-induced collagen content. (A) Assessment of caspase-3 activity in wild-type and 
lpr mouse lung fibroblasts transfected with pcDNA3.1, wild-type Fas, or C294A mutant Fas; pretreated with TLK117 for 2 hours; and treated with FASL 
for 4 hours. *P < 0.05 relative to respective vehicle/control group, †P < 0.05 relative to respective vehicle/FASL group, ‡P < 0.05 relative to respective 
wild-type FAS construct group by 1-way ANOVA with a Tukey post-test (n = 3 per group, representative of 2 independent experiments). (B) Assessment 
of caspase-3 activity in mouse type II alveolar epithelial cells following TLK117 pretreatment for 2 hours and treatment with either FASL or TNF-α with 
cycloheximide for 4 hours. *P < 0.05 relative to respective vehicle/control group, †P < 0.05 relative to respective vehicle/FASL group by 1-way ANOVA 
with a Tukey post-test (n = 6 per group, representative of 2 independent experiments). (C) Evaluation of GSTP activity in mouse lungs following oro-
pharyngeal administration of either 25 or 50 mg/kg TLK117 for 4 or 24 hours. *P < 0.05 relative to vehicle control by 1-way ANOVA (n = 3 per group). (D) 
Schematic of the TLK117 treatment strategy with the bleomycin model. (E and F) Assessment of hydroxyproline and soluble collagen content in mouse 
lung homogenates. *P < 0.05 relative to PBS group, †P < 0.05 relative to 15-day bleomycin group, ‡P < 0.05 relative to 28-day bleomycin/vehicle group by 
1-way ANOVA with a Tukey post-test. Shown are pooled data from 2 independent experiments (n = 6 per group). (G) Assessment of fibrotic remodeling 
by Masson’s trichrome staining. (H) Assessment of α-SMA immunoreactivity by immunohistochemistry (red, α-SMA, blue, hematoxylin). Scale bar: 100 
μm. lpr, Fas-deficient; GSTP, glutathione-S-transferase π; α-SMA, α-smooth muscle actin; Bleo, bleomycin; Veh, vehicle; TLK, TLK117; FASL, FAS ligand; 
TNF, TNF-α; CHX, cycloheximide; RLU, relative luminescence units; Euth, euthanasia.
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Figure 5. TLK117-mediated GSTP inhibition attenuates AdTGFβ-induced collagen content. (A) Schematic of the TLK117 treatment strategy with the 
AdTGFβ model. (B and C) Assessment of hydroxyproline and soluble collagen content in mouse lung homogenates. *P < 0.05 relative to AdCtrl group, 
†P < 0.05 relative to 14-day AdTGFβ group, ‡P < 0.05 relative to 28-day AdTGFβ/vehicle group by 1-way ANOVA with a Tukey post-test. Shown are 
pooled data from 2 independent experiments (n = 5–16 per group). (D) Assessment of fibrotic remodeling by Masson’s trichrome staining. (E) Assess-
ment of α-SMA immunoreactivity by immunohistochemistry (red, α-SMA; blue, hematoxylin). Scale bar: 100 μm. AdCtrl, control adenovirus; AdTGFβ, 
adenovirus expressing active TGF-β1; α-SMA, α-smooth muscle actin; Euth, euthanization.
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ed that formation of  a sulfenic acid intermediate precedes GSTP-catalyzed S-glutathionylation of  FAS 
in lung epithelial cells exposed to FASL (8). It remains unclear whether, in settings of  lung fibrosis, a 
sulfenic acid residue of  FAS is required for GSTP-catalyzed S-glutathionylation. The source of  oxidants 
required for FAS-SSG also remains unclear. Previous studies have illuminated the importance of  NOX4 
activation as a source of  hydrogen peroxide (H2O2) in myofibroblasts and have indicated that release of  
H2O2 from fibroblasts is an important signal for apoptosis of  epithelial cells (39–41). A prior study from 
our laboratory demonstrated that oxidative processing of  latent FAS within the endoplasmic reticulum 
generates H2O2, which enables subsequent FAS-SSG (8). Further studies will therefore be required to 
identify the importance of  H2O2 and the source of  its production for GSTP-linked S-glutathionylation 
in settings of  fibrosis. While FAS signaling is important for epithelial cell apoptosis, it has also been 
linked to myofibroblast activation, proliferation, and evasion from apoptosis (6, 9, 42–44). Our current 
study did not determine whether GSTP and S-glutathionylation chemistry plays a role in myofibroblast 
behavior, which will require additional investigation. In addition to GSTP, it is possible that other GST 
isoforms may be involved in S-glutathionylation and pulmonary fibrosis as well. GSTM, GSTT, and 
GSTO polymorphisms have been linked to lung cancer, asthma, and COPD (45–49) and to PSSG (38). 
Further research will be required to elucidate the role other GSTs in S-glutathionylation and lung fibro-
sis. Despite the profibrogenic role of  GSTP described in the present study, it is important to acknowledge 
that GSTP has important homeostatic functions. GSTP plays a prominent role in detoxification of  the 
unsaturated aldehyde, acrolein (38). Ablation of  Gstp has been shown to increase endothelial dysfunc-
tion in response to cigarette smoke, which contains high levels of  acrolein (38). Similarly, absence of  
Gstp enhanced myocardial sensitivity to ischemia/reperfusion injury in association with increased acro-
lein-adducted proteins (49). Thus, the potential protective effect of  inhibition of  GSTP will likely be 
context specific.
Of  significant clinical interest is the administration of  the GSTP-specific inhibitor, TLK117. The 
development of  TLK117 and its prodrug, TLK199, was prompted by the discovery that GSTP inhibition 
promotes myeloid cell hyperplasia by promoting c-Jun N-terminal kinase (JNK) activation by disrupting 
Figure 6. TLK117-mediated GSTP inhibition attenuates bleomycin-induced caspase activation and protein S-glutathionylation. Wild-type mice were 
treated with bleomycin and subsequently with TLK117, as described in Figure 4D. (A and B) Measurement of caspase-3 and -8 activity in mouse lungs 
homogenates. (C) Measurement of total PSSG with a modified DTNB assay. (A–C) *P < 0.05 relative to PBS group, †P < 0.05 relative to 15-day bleomy-
cin group, ‡P < 0.05 relative to 28-day bleomycin/vehicle group by 1-way ANOVA with a Tukey post-test. Shown are pooled data from 2 independent 
experiments (n = 5–6 per group). (D) Assessment of FAS-SSG by immunoprecipitation of total PSSG and Western blot for FAS. Significant differences 
between 28-day bleomycin-treated vehicle and TLK117 groups were assessed by densitometric analysis. *P < 0.05 by 2-tailed unpaired Student’s t test 
(n = 3 per group). Data shown in D are representative of 1 of 2 independent experiments. FAS-SSG, S-glutathionylated FAS; GSH, glutathione; Bleo, 
bleomycin; DTT, dithiothreitol; WB, Western blot.
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GSTP-JNK interaction (24, 26, 33, 50). JNK signaling is an important mediator in lung inflammation and 
remodeling, and we have demonstrated a causal role for JNK1 in the development of  pulmonary fibrosis 
(51–53). It is possible that TLK117-mediated inhibition of  GSTP may also block lung fibrogenesis through 
a mechanism involving JNK signaling. Interestingly, the data presented in Figures 4 and 5 demonstrate that 
TLK117 may be capable not only of  attenuating fibrosis progression, but also of  reversing existing increas-
es in collagen content, although additional studies will be necessary to elucidate the impact of  TLK117 
in additional models of  persistent fibrosis, including age-associated pulmonary fibrosis. It is possible that 
TLK117-mediated GSTP inhibition stimulates collagen degradation through upregulation or activation of  
collagenases. Intriguingly, the JNK pathway has been shown to regulate matrix metalloproteinases (54, 55), 
which are essential for collagen clearance and reepithelialization during wound healing (56). Future stud-
ies will therefore be aimed at obtaining mechanistic insights into how GSTP-linked PSSG affects matrix 
degrading pathways and the subsequent impact on fibrotic remodeling in the lung.
Bleomycin-induced fibrosis, FAS-SSG, and caspase activation in mouse lungs are all abundant about 
2 weeks after treatment (8, 18). Therefore, administration of  TLK117 at this time was chosen to address 
the impact of  TLK117 in settings of  existing fibrosis. Controversy exists regarding the clinical relevance of  
bleomycin as a model of  IPF, largely because its mechanism of  action is not fully known and because bleo-
mycin-induced lung fibrosis resolves in adult mice (18, 57). The observations herein, however, demonstrate 
a similar protective impact of  genetic ablation or inhibition of  GSTP in the AdTGFβ model of  fibrosis, 
Figure 7. TLK117-mediated GSTP inhibition attenuates AdTGFβ-induced caspase activation and protein S-glutathionylation. Wild-type mice were 
treated with AdTGFβ and subsequently with TLK117, as described in Figure 5A. (A and B) Measurement of caspase-3 and -8 activity in mouse lung 
homogenates. (C) Measurement of total PSSG with a modified DTNB assay. (A–C) *P < 0.05 relative to AdCtrl group, †P < 0.05 relative to 14-day AdTGFβ 
group, ‡P < 0.05 relative to 28-day AdTGFβ/vehicle group by 1-way ANOVA with a Tukey post-test. Shown are pooled data from 2 independent experi-
ments (n = 5–16 per group). (D) Assessment of FAS-SSG by immunoprecipitation of total PSSG and Western blot for FAS. (E) Assessment of FAS-GSTP 
interaction by immunoprecipitation of FAS from whole-lung homogenates and detection of GSTP by Western blot. Significant differences between 
28-day AdTGFβ-treated vehicle and TLK117 groups were assessed by densitometric analysis. *P < 0.05 by 2-tailed unpaired Student’s t test (n = 3 per 
group for D and n = 3–5 per group for E). The data shown in D and E are representative of 1 of 2 independent experiments. GSTP, glutathione-S-transfer-
ase π; FAS-SSG, S-glutathionylated FAS; AdCtrl, control adenovirus; AdTGFβ, adenovirus expressing active TGF-β1; GSH, glutathione; DTT, dithiothreitol; 
WB, Western blot; IgG, immunoglobulin control.
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which is believed to induce persistent remodeling (7). The demonstration of  a protective effect of  TLK117 
or GSTP ablation in both models, along with the demonstration of  increases in GSTP and associations 
between GSTP and FAS in lung tissues from patients with IPF, collectively points to a putative causal role 
of  GSTP-linked S-glutathionylation in patients with IPF.
Clinical trials utilizing TLK199 have shown that this compound is well-tolerated and exerts only minor 
gastrointestinal side effects (23), which may be anticipated given the abundance of  GSTP in the stomach 
and intestinal epithelium (32, 58). Patients exposed to high doses of  TLK199 also exhibited an increased 
incidence and severity of  abnormal skin odor (23). The dosing regimen of  TLK199 in clinical trials, how-
ever, was either intravenous or oral rather than via the airways (22, 23). Further, given the short half-life of  
this drug when administered via intravenous or oral routes, patients were given daily doses of  up to 4,500 
mg to exert therapeutic effects (23). It is possible that administration of  active TLK117 or the prodrug, 
TLK199, via inhalation could also have a beneficial effect in patients with IPF, and such a dosing regimen 
would be an attractive strategy to directly target GSTP-expressing epithelial cells. However, additional clin-
ical testing with these compounds using an inhalation regimen will be required to establish the feasibility 
of  this approach in patients.
New therapies for pulmonary fibrosis have been the subject of  much research and intense pharmaceu-
tical development in recent years. Corticosteroids and immunosuppressants have routinely demonstrated to 
be of  limited efficacy and to elicit potent side effects in IPF patients (59–62). Pirfenidone and nintedanib, 
the most promising recent additions to this repertoire, have modest effects on lung function decline (63–
65). Antioxidants have been proposed as potential therapeutics for fibrotic lung diseases, particularly the 
GSH precursor, N-acetylcysteine (66). However, a recent phase III clinical trial demonstrated no beneficial 
effects of  N-acetylcysteine on IPF progression or lung function decline (4), although a pharmacogenomic 
interaction involving TOLLIP and MUC5B SNPs and a response of  IPF patients to N-acetylcysteine has 
become apparent (67). The current study points to the importance not of  GSH per se, but a unique facet of  
GSH chemistry, which involves its covalent incorporation into proteins, catalyzed by GSTP, a biochemical 
pathway that has not previously been recognized in settings of  pulmonary fibrosis. Thus, a clinical trial 
utilizing the GSTP inhibitor described herein in IPF patients appears well warranted and may yield new 
insights into the functional importance of  S-glutathionylation chemistry in the pathogenesis and progres-
sion of  this deadly disease.
Methods
Additional details are available in the Supplemental Methods.
Study design. The aim of  this study was to determine the effects of  Gstp knockout and GSTP inhibition 
on two mouse models of  lung fibrosis (bleomycin and AdTGFβ). All studies were age and sex matched, and 
each experiment was conducted at least twice with a minimum of  8 mice per group based on experiments 
conducted previously (8, 51–53). Endpoints, including changes in collagen content, α-SMA immunoreac-
tivity, FAS-SSG, total PSSG, and FAS-GSTP interaction, between 2 and 4 weeks were selected based on 
previously reported findings (7, 8, 18). GSTP expression and FAS-GSTP interaction were also measured in 
human IPF lung samples relative to healthy controls, and at least 10 samples per group were analyzed. The 
effects of  Gstp and Fas deficiency (Lpr genotype) and reconstitution on caspase activity were also measured 
in lung fibroblasts in vitro; each in vitro experiment was conducted at least twice, each time in triplicate. All 
data collected for each experiment is represented in the figures, and no outliers were excluded.
Human lung samples. Deidentified human lung samples from both normal and IPF patients were 
obtained from the Lung Tissue Research Consortium (LTRC).
Mice. Male and female C57BL/6NJ mice, both wild-type and deficient for both Gstp1 and 2 (Gstp–/–) 
(68, 69), were bred at the University of  Vermont and used at 8 weeks of  age. Mice were treated with either 
bleomycin (0.125 U/mouse) or AdTGFβ (5 × 108 pfu/mouse) oropharyngeally to induce lung fibrotic 
remodeling. PBS and an adenovirus expressing an empty vector (AdCtrl) were used as controls, respective-
ly. In the bleomycin model, mice were euthanized at either day 15 or 28. In the AdTGFβ model, mice were 
euthanized at day 21. Right lung lobes were frozen for detection of  collagen content, FAS-SSG, total PSSG, 
FAS-GSTP interaction, mRNA production, and protein expression. Left lobes were fixed in 4% parafor-
maldehyde in PBS, embedded in paraffin, and sectioned for immunohistochemical analysis.
Cells. Primary normal lung fibroblasts from both wild-type and Lpr mice, and mouse type II alveolar 
epithelial (C10) cells, were obtained and cultured as previously described (8). Lpr fibroblasts were transfect-
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ed with constructs expressing either wild-type or C294A mutant Fas using Lipofectamine LTX with PLUS 
reagent according to the manufacturer’s protocol (A21621; Invitrogen). pcDNA3.1 was used as a control. 
Wild-type fibroblasts remained untransfected throughout the experiment. Fibroblasts and type II cells were 
pretreated with 50 μM of  the active GSTP inhibitor, TLK117, in serum-free media for 2 hours and subse-
quently with 500 ng/ml of  FASL (ALX-522-001; Enzo Life Sciences) with 1 μg/ml of  anti-FLAG cross-
linking antibody (M2; F1804; Sigma-Aldrich) for 4 hours as previously described (8). M2 only was used as 
a control. Type II cells were also treated with 10 ng/ml mouse TNF-α (GF027; EMD Millipore) and 5 μg/
ml cycloheximide (Sigma-Aldrich) for 4 hours. Cells were then lysed in a NP-40 lysis buffer supplemented 
with protease and phosphatase inhibitors to collect protein.
Synthesis of  TLK117. TLK117 [γ-glutamyl-S-(benzyl)cysteinyl-R-(–)-phenyl glycine] was generated by 
Fmoc solid-state peptide synthesis with HBTU as previously described (8) and was confirmed to be >98% 
pure by HPLC. TLK117 was administered oropharyngeally at a dose of  50 mg/kg in a 0.375 M Tris-HCl 
solution, pH = 7.4, with 0.02% DMSO. This Tris-HCl/DMSO solution was used as a vehicle control. 50 
mg/kg was selected based on the data presented in Figure 6A. Treatments were performed once every 3 
days from day 14 to day 26 in both bleomycin and AdTGFβ models for a total of  5 treatments. Mice that 
were euthanized at day 15 in the bleomycin model and day 14 in the AdTGFβ model did not receive either 
TLK117 or the vehicle control.
Detection of  FAS-GSTP interaction. Human lung samples obtained from the LTRC were homogenized 
in an NP-40 lysis buffer containing 10% glycerol and protease and phosphatase inhibitors as previously 
described (8). FAS was isolated by immunoprecipitation with an anti-FAS antibody (554254; BD Bio-
sciences) and recombinant protein G agarose beads (15920-010; Invitrogen), and GSTP was detected by 
Western blot with a GSTP-specific antibody (312; MBL International).
Detection of  FAS-SSG. Mouse lungs were homogenized in a Tris/SDS lysis buffer, pH = 7.4, supple-
mented with protease and phosphatase inhibitors, 20 mM N-ethylmaleimide, 100 μM diethylene triamine 
pentaacetic acid, and 100 μM neocuproine (Sigma-Aldrich). PSSGs were isolated from mouse lung homog-
enates by immunoprecipitation with a PSSG-specific antibody (101-A; ViroGen) and recombinant protein 
G agarose beads (Invitrogen) as previously described (10). As a control, lysate was pretreated with 50 μM 
DTT to reduce PSSG also as previously described (10). Both total FAS and FAS-SSG content was assessed 
by Western blot with an anti-FAS antibody (05-351; EMD Millipore).
Detection of  total PSSG content. Total PSSG content was detected in mouse lungs with a modified DTNB 
assay as previously described (8, 70).
GSTP activity assay. Mouse lungs were homogenized in a 100 mM potassium phosphate buffer, pH = 
6.5, with protease and phosphatase inhibitors and 0.1% Triton X-100. GSTP was isolated from homoge-
nates by immunoprecipitation with a GSTP-specific antibody (MBL International) and recombinant pro-
tein G agarose beads (Invitrogen) as previously described (8). Normal rabbit IgG was used as a control. 
Beads were washed and resuspended in 100 mM potassium phosphate buffer, pH = 6.5, with 1 mM EDTA, 
and GSTP activity was assessed with a modified CDNB assay as previously described (8). Results are 
expressed as nmol substrate per mg protein per minute, wherein one unit represents the consumption of  
substrate by 1 mg of  GSTP per minute.
Caspase activity. Caspase-3 and -8 activity was measured with Caspase-Glo activity reagents (G8091 and 
G8201; Promega) according to the manufacturer’s instructions.
Assessment of  collagen content. Hydroxyproline content was assessed in the right upper lobe of  the lung 
as previously described (71). Lobes were digested overnight in 6 N HCl and mixed with chloramine-T for 
20 minutes and with perchloric acid for 5 minutes at room temperature. Ehrlich’s reagent was added for 20 
minutes at 60°C, and absorbance was measured at 561 nm. All reagents were obtained from Sigma-Aldrich. 
Soluble collagen was assessed from the right middle lobe of  the lung as previously described (72). Lobes 
were digested overnight with 10 mg pepsin in 0.5 M acetic acid, and collagen content was assessed with a 
Sircol collagen assay kit according to the manufacturer’s instructions (S1000; Biocolor Life Science).
Tissue staining and immunohistochemistry. Fibrotic remodeling was assessed in mouse lung sections by 
Masson’s trichrome staining. For immunohistochemical analysis, human lung sections from the LTRC were 
probed with antibodies specific for GSTP (MBL International) and pro-SPC (AB3786; EMD Millipore). 
Mouse lung sections were probed for either GSTP (AP9199c; Abgent) or α-SMA (A2547; Sigma-Aldrich). 
All sections were developed with a universal Vectastain ABC-AP kit (AK-5200; Vector Laboratories) and 
a Vector Red AP substrate kit (SK-5100; Vector Laboratories) and were counterstained with hematoxylin. 
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Slides were subsequently coverslipped, viewed, and photographed as previously described (8). Each scale 
bar represents either 50 or 100 μm as indicated.
Western blotting. Protein concentration in whole lung homogenates was determined using a DC protein 
assay (Bio-Rad), and 25 μg of  total protein was separated via 8% SDS-PAGE, transferred onto Immobi-
lon-P membrane (IPVH00010; EMD Millipore), and blocked with 5% BSA in TBS with 0.1% Tween 20. 
The mouse β-actin antibody was purchased from Sigma-Aldrich (A5441). Protein was visualized using 
an ECL Western blotting substrate (32106; Thermo Fisher Scientific) and developed on blue X-ray film 
(F-BX810; Phenix Research Products) with a Summit QCP X-ray film processor. Densitometric analysis 
was performed with Discovery Series Quantity One 1-D analysis software (Bio-Rad).
Statistics. Statistical analysis was performed with GraphPad Prism v6.0 (GraphPad Software). All 
results are presented as the mean ± SEM. Statistically significant differences were assessed with a 1-way 
ANOVA with a Tukey post-test, a 2-way ANOVA with a Tukey post-test, or a 2-tailed unpaired Student’s t 
test where appropriate. A P value of  less than 0.05 was considered significant.
Study approval. The Institutional Review Board of  the University of  Vermont has determined that the 
use of  the deidentified human samples used in this study does not constitute human subjects research as 
recognized by 45 CFR 46.102(f) and the US Department of  Health and Human Services Office for Human 
Research Protections Guidance on Research Involving Coded Private Information or Biological Speci-
mens. All studies involving mice were approved by the Institutional Animal Care and Use Committee at 
the University of  Vermont.
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